The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 22, 2022

Filed:

Jan. 11, 2017
Applicant:

Cedars-sinai Medical Center, Los Angeles, CA (US);

Inventors:

Eduardo Marban, Santa Monica, CA (US);

Romain Gallet, Paris, FR;

Assignee:

Cedars-Sinai Medical Center, Los Angeles, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 35/34 (2015.01); C12N 5/077 (2010.01); A61P 9/04 (2006.01); A61K 9/00 (2006.01);
U.S. Cl.
CPC ...
A61K 35/34 (2013.01); A61K 9/0019 (2013.01); A61P 9/04 (2018.01); C12N 5/0657 (2013.01);
Abstract

Heart failure with preserved ejection fraction (HFpEF) is a disease condition characterized by heart failure (HF) signs and symptoms, but with normal or near normal left ventricular ejection fraction (LVEF) and is not responsive to standard therapy for treatment of HF. Described herein are compositions and methods related to use of cardiosphere derived cells (CDCs) and their exosomes to improve left ventricular structure, function and overall outcome. Administration of CDCs led to improved LV relaxation, lower LV end-diastolic pressure, decreased lung congestion and enhanced survival. Lower risk of arrhythmias in HFpEF was also observed following CDC administration. Improvement of diastolic dysfunction following administration of CDC-derived exosomes was observed, along with decreased mortality. In view of these salutary effects, CDCs and CDC-derived exosomes are beneficial in the treatment of HFpEF.


Find Patent Forward Citations

Loading…